netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Results

Looking for Adalimumab found 28 matches

Formulary items 2 matches
   
Formulary BNF Category
  Adalimumab
(See 10.01.03 for preparations)
Cytokine inhibitors - 01.05.03
  Adalimumab  (Humira) Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
link in subsection NICE TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA146: Adalimumab for the treatment of adults with psoriasis (10.01.03)
link in drug section NICE TA146: Psoriasis - adalimumab (13.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)


 

netFormulary